Erratum: The IL-6R α chain controls lung CD4+CD25 + Treg development and function during allergic airway inflammation in vivo (Journal of Clinical Investigation (2005) 115 (313-325) DOI: 10.1172/JCI200522433);The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 313-325

  Doganci, Aysefa ^a   Eigenbrod, Tatjana ^a   Krug, Norbert ^b   De Sanctis, George T ^c   Hausding, Michael ^a   Erpenbeck, Veit J ^b   Haddad, El Bdaoui ^b   Schmitt, Edgar ^a   Bopp, Tobias ^a   Kallen, Karl J ^d   Herz, Udo ^e   Schmitt, Steffen ^a   Luft, Cornelia ^a   Hecht, Olaf ^b   Hohlfeld, Jens M ^b   Ito, Hiroaki ^f   Nishimoto, Norihiro ^f   Yoshizaki, Kazuyuki ^g   Kishimoto, Tadamitsu ^g   Rose John, Stefan ^d   Renz, Harald ^e   Neurath, Markus F ^a   Galle, Peter R ^a   Finotto, Susetta ^a   more..

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^c SANOFI   (France)

^d UNIVERSITY OF KIEL   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f OSAKA UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE ANTIBODY; GAMMA INTERFERON; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN E; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; MESSENGER RNA; METHACHOLINE; OVALBUMIN; RAG1 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIBODY; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR, GLM R; CYTOKINE RECEPTOR, GLM-R; DNA BINDING PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; FOXP3 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; INTERLEUKIN 2 RECEPTOR; RAG 1 PROTEIN; RAG-1 PROTEIN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN;

ADOPTIVE TRANSFER; ADULT; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE DEFICIENCY; IN VIVO STUDY; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; T LYMPHOCYTE; TH2 CELL; ANIMAL; ASTHMA; DRUG EFFECT; GENETICS; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; MOUSE MUTANT; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT; ANIMALS; ANTIBODIES; ASTHMA; DNA-BINDING PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; HUMANS; HYPERSENSITIVITY; INFLAMMATION; LUNG; MALE; MICE; MICE, KNOCKOUT; OVALBUMIN; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-2; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TH2 CELLS; TRANS-ACTIVATORS;

EID: 20144375594     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200522433C1     Document Type: Erratum

References (53)

1. Holgate, S.T. 1999. The epidemic of allergy and asthma. Nature. 402:B2-B4.
2. Robinson, D.S., et al. 1993. Activation of CD4+ T cells, increased Th2-type mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J. Allergy Clin. Immunol. 92:313-324.
3. Robinson, D.S., et al. 1992. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326:298-304.
4. Tang, C., Rolland, J.M., Ward, C., Quan, B., and Waters, E.H. 1997. IL-5 production by bronchoalveolar lavage and peripheral blood mononuclear cells in asthma and atopy. Eur. Respir. J. 10:624-632.
5. Ying, S., et al. 1993. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am. J. Respir. Cell Mol. Biol. 4:356-360.
6. Neurath, M.F., Finotto, S., and Glimcher, L.H. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8:567-573.
7. Zhu, Z., et al. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103:779-788.
8. Temann, U.A., Ray, P., and Flavell, R.A. 2002. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J. Clin. Invest. 109:29-39. doi: 10.1172/ JCI200213696.
9. Akbari, O., et al. 2003. Essential role of NKT cells producing IL-4 and 1L-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582-588.
10. Rincon, M., Anguita, J., Nakamura, T., Fikrig, E., and Flavell, R.A. 1997. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J. Exp. Med. 185:461-469.
11. Diehl, S., et al. 2002. Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. J. Exp. Med. 196:39-49.
12. Dodge, I.L., Carr, M.W., Cernadas, M., and Brenner, M.B. 2003. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J. Immunol. 170:4457-4464.
13. Peters, M., Müller, A., and Rose-John, S. 1998. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood. 92:3495-3504.
14. Romano, M., et al. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 5:315-325.
15. Rose-John, S., and Heinrich, P.C. 1994. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300:281-290.
16. Teague, T.K., Marrack, P., Kappler, J.W., and Vella, A.T. 1997. 1L-6 rescues resting mouse T cells from apoptosis. J. Immunol. 158:5791-5796.
17. Naka, T., Nishimoto, N., and Kishimoto, T. 2002. The paradigm of IL-6: from basic science to medicine. Arthritis. Res. 4:S233-S242.
18. Choy, E.H., et al. 2002. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis. Arthritis Rheum. 46:3143-3150.
19. Schunnga, J.J., Dekker, L.V., Vellenga, E., and Kruijer, W. 2001. Sequential activation of Rac-1, SEK-1/ MKK-4 and PKCdelta is required for interleukin-6 induced STAT3 Ser-727 phosphorylation and transactivation. J. Biol. Chem. 29:27709-27715.
20. Minami, M., et al. 1996. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc. Natl. Acad. Sci. U. S. A. 93:3963-3966.
21. Novotny-Diermayr, V., Zhang, T., Gu, L., and Cao, X. 2002. Protein kinase C delta associates with the interleukin-6 receptor subunit glycoprotein (gp) 130 via Stat3 and enhances Stat3-gp130 interaction. J. Biol. Chem. 277:49134-49142.
22. Fukada, T., et al. 1996. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 5:449-460.
23. Akira, S. 1996. IL-6-regulated transcription factors. Int. J. Biochem. Cell Biol. 29:1401-1418.
24. Chow, D., He, X., Snow, A.L., Rose-John, S., and Garcia, K.C. 2001. Structure of an extracellular gp130 cytokine receptor signaling complex. Science. 291:2150-2155.
25. Hurst, S.M., et al. 2001. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 14:705-714.
26. Broide, D.H., et al. 1992. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89:958-967.
27. Jones, S.A., Horiuchi, S., Topley, N., Yamamoto, N., and Fuller, G.M. 2001. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15:43-58.
28. Tamura, T., et al. 1993. SIL-6R triggers osteoclast formation by IL-6. Proc. Natl. Acad. Sci. U. S. A. 90:11924-11928.
29. Kallen, K.J. 2002. The role of transsignaling via the agonistic sIL-6R in human diseases. Biochim. Biophys. Acta. 1592:323-343.
30. Rose-John, S., and Neurath, M.F. 2004. IL-6 transsignaling: the heat is on. Immunity. 20:2-4.
31. Atreya, R., et al. 2000. Blockade of IL-6 transsignaling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. 6:583-588.
32. Yokoyama, A., et al. 1997. Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma. Am. J. Respir. Crit. Care. Med. 156:1688-1691.
33. Zhang, D.H., et al. 1999. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity. 11:473-482.
34. Finotto, S., et al. 2001. Treatment of allergic airway inflammation and hyperresponsiveness by local antisense-induced blockade of GATA-3 expression. J. Exp. Med. 193:1247-1260.
35. Maloy, K.J., and Powric, P. 2001. Tregs in the control of immune pathology. Nat. Immunol. 2:816-822.
36. Belkaid, Y., Piccirillo, C.A., Mendez, S., Shevach, E.M., and Sacks, D.L. 2002. CD4+CD25+ Tregs control Leishmania major persistence and immunity. Nature. 420:502-507.
37. Pasare, C., and Medzhitov, R. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 299:1033-1036.
38. Fantini, M.C., et al. 2004. TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172:5149-5153.
39. Powrie, F., and Maloy, K.J. 2003. Regulating the regulators. Science. 299:1030-1031.
40. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of Treg development by the transcription factor Foxp3. Science. 299:1057-1061.
41. Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. 2003. An essential role for Scarfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4:337-342.
42. Fontenot, J.D., Gavin, M.A., and Rudensky, Y.A. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory cells. Nat. Immunol. 4:330-336.
43. O'Garra, A., and Vieira, P. 2003. Twenty-first century Foxp3. Nat. Immunol. 4:304-306.
44. Croker, B.A., et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:507-509.
45. Akbari, O., et al. 2002. Antigen-specific Tregs develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8:1024-1032.
46. Stock, P., et al. 2004. Induction of T helper type 1-like regulatory cells that express Foxp3 and protect against airway hyper-reactivity. Nat. Immunol. 5:1149-1156.
47. National Heart, Lung, and Blood Institute. 1992. International consensus report on diagnosis and treatment of asthma. Eur. Respir. J. 5:601-641.
48. Erpenbeck, V.J., et al. 2003. Local release of eosinophil peroxidase following segmental allergen provocation in asthma. Clin. Exp. Allergy. 33:331-336.
49. Krug, N., et al. 2001. Cytokine profile of bronchoalveolar lavage derived CD4+, CD8+ and gd T cells in people with asthma after segmental allergen challenge. Am. J. Respir. Cell Mol. Biol. 25:125-131.
50. Henderson, W.R., Jr., et al. 1997. Blockade of CD49d (α4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. 100:3083-3092.
51. De Sanctis, G.T., et al. 1997. T-lymphocytes regulate genetically determined airway hyperresponsiveness in mice. Nat. Med. 3:460-462.
52. De Sanctis, G.T., et al. 1995, Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. Nat. Genet. 11:150-154.
53. Finotto, S., et al. 2002. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science. 295:336-338.